Helius Medical Technologies Announces Participation in Upcoming Healthcare Conferences
Helius Medical Technologies, a neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, has announced the participation of Jeff Mathiesen, Chief Financial Officer, at two upcoming conferences. The first is the JonesTrading 2023 Healthcare Summit in Miami, Florida, on October 10, 2023, and the second is the Roth 2023 Healthcare Opportunities Conference in New York City on October 12, 2023. Investors and attendees interested in scheduling a one-on-one meeting with Helius management are encouraged to contact the respective conference organizers.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company focused on developing medical devices that address neurologic deficits. Their technology platform amplifies the brain's ability to engage compensatory mechanisms and promote neuroplasticity, ultimately improving the lives of individuals with neurologic diseases. The company's Portable Neuromodulation Stimulator (PoNS) is their first commercial product, delivering neurostimulation through a mouthpiece to improve balance and gait.
PoNS Therapy and Effectiveness
The Portable Neuromodulation Stimulator (PoNS) is a non-implantable therapy that uses mild electrical impulses delivered through the tongue to stimulate the brain. In the United States, it is indicated for short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (MS) and is used in conjunction with physical therapy. In Canada, PoNS has shown effectiveness in treating gait deficit and reducing the risk of falling in stroke patients, as well as improving chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI). It is also authorized for sale in Australia for short-term use by healthcare professionals to improve balance and gait.
In conclusion, Helius Medical Technologies' participation in these healthcare conferences provides an opportunity for industry professionals and investors to learn more about their innovative neurotech solutions. The company's focus on therapeutic neuromodulation and their Portable Neuromodulation Stimulator (PoNS) demonstrate their commitment to improving the lives of individuals with neurologic deficits.
Helius Medical Technologies' Participation in Healthcare Conferences: A Game Changer for New Businesses?
Helius Medical Technologies' announcement of their participation in two upcoming healthcare conferences could have significant implications for new businesses in the healthcare sector. The neurotech company, recognized for its innovative therapeutic neuromodulation approach to balance and gait deficits, will be represented by its CFO, Jeff Mathiesen, at the JonesTrading 2023 Healthcare Summit and the Roth 2023 Healthcare Opportunities Conference.
The Potential Impact on New Businesses
This move by Helius could potentially set a new standard for how businesses present themselves to potential investors and industry professionals. The company's focus on showcasing its Portable Neuromodulation Stimulator (PoNS), a device that improves balance and gait by delivering neurostimulation through a mouthpiece, demonstrates their commitment to improving the lives of individuals with neurologic diseases.
Setting a Benchmark for Innovation
Helius' participation in these conferences not only provides an opportunity for industry professionals and investors to learn more about their groundbreaking neurotech solutions, but it also serves as a benchmark for innovation for new businesses. The company's focus on therapeutic neuromodulation and their PoNS technology could inspire new businesses to strive for similar levels of innovation and commitment to improving patient outcomes.
In conclusion, Helius Medical Technologies' proactive approach to networking and showcasing their products at healthcare conferences could have a profound influence on how new businesses strategize their growth and development within the healthcare sector.
.svg)
